Compare LILA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LILA | NTLA |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Bermuda | United States |
| Employees | 10000 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2016 |
| Metric | LILA | NTLA |
|---|---|---|
| Price | $8.05 | $12.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 18 |
| Target Price | $9.75 | ★ $18.34 |
| AVG Volume (30 Days) | 367.1K | ★ 4.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $57,877,000.00 |
| Revenue This Year | N/A | $1.71 |
| Revenue Next Year | $7.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 59.55 |
| 52 Week Low | $4.25 | $5.90 |
| 52 Week High | $9.04 | $28.24 |
| Indicator | LILA | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 54.55 |
| Support Level | $7.90 | $10.44 |
| Resistance Level | $8.25 | $14.61 |
| Average True Range (ATR) | 0.39 | 0.85 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 53.74 | 68.14 |
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.